Complete coverage — every Article 1–123, every Annex I–XVII. 22 modules of scenario-based gamified learning.
Reference answers maintained by SKY Biotechnology, a CE marked and ISO 13485 certified medical device manufacturer in Pendik, Istanbul, Turkiye. Provided for information and does not constitute regulatory advice.
Intra-articular viscosupplementation gels are classified under Annex VIII Rule 8 as long-term surgically invasive implantable devices, and fall into Class III under Rule 14 where they incorporate a medicinal substance. In this class the manufacturer is subject to a full quality assurance system audit under Annex IX Chapter I and technical documentation assessment under Chapter II; alternatively Annex X type examination combined with Annex XI Part A product conformity verification may be selected. Mandatory elements include a technical file structured to Annexes II and III; an Annex I General Safety and Performance Requirements checklist; a risk management file to ISO 14971:2019; the ISO 10993 biocompatibility series together with local effect assessment for the intra-articular route; rheological characterisation, molecular weight distribution, degree of cross-linking, endotoxin and sterility data; and ISO 11607 packaging validation with shelf life. Clinically, evaluation is performed under Article 61; for Class III implantable devices clinical investigation is the rule, and exemption via equivalence is possible only where full contractual access to the equivalent device technical documentation is demonstrated under Article 61(4) and 61(5). The Notified Body assessment is additionally referred to the clinical evaluation consultation procedure by an expert panel under Article 54 and Annex IX Section 5.1. Post-market obligations comprise an annual PSUR, a PMCF plan and report, Basic UDI-DI and UDI-DI registration in EUDAMED under Annex VI Part C, publication of a Summary of Safety and Clinical Performance under Article 32, and financial liability coverage proportionate to device class and manufacturer size under Article 10(16).
Regulation (EU) 2023/607 extended the transition periods, but the extension is conditional. There must be no significant change in the design or intended purpose of the device; the quality management system must have been brought into conformity with MDR under Article 10(9) by 26 May 2024; a formal application must have been lodged with a Notified Body by the same date; and a written agreement must have been signed by 26 September 2024. Where these conditions are met, the deadline is 31 December 2027 for Class III and implantable Class IIb devices, and 31 December 2028 for other Class IIb, Class IIa and sterile or measuring-function Class I devices. A manufacturer relying on the conditional extension must nevertheless comply in full with the MDR provisions on post-market surveillance, vigilance, registration of economic operators and registration of devices throughout the transition. In practice the most labour-intensive items are restructuring the clinical evaluation to the MDCG 2020-6 evidence hierarchy, remapping the requirements from MDD Annex I to MDR Annex I, and updating labelling and instructions for use to Annex I Chapter 23 requirements, including the UDI carrier, the MD symbol, and compliance with Regulation (EU) 2021/2226 where electronic instructions for use are supplied.
Under Article 11 a manufacturer established outside the EU must appoint an Authorised Representative by written mandate for every device placed on the EU market. The tasks of the representative are enumerated in Article 11(3) and include keeping a copy of the technical documentation, liaising with competent authorities, and bearing joint and several liability with the manufacturer for defective devices under Article 11(5). The manufacturer and authorised representative register in EUDAMED under Article 31 to obtain a Single Registration Number, after which the Basic UDI-DI and UDI-DI of the device are entered under Article 29. Under Article 15 both the manufacturer and the authorised representative must have a Person Responsible for Regulatory Compliance meeting the prescribed qualification and experience criteria. The importer under Article 13 and the distributor under Article 14 must verify CE marking, the declaration of conformity, the UDI and the correctness of label language, maintain complaint records, and report non-conformities to the manufacturer. All devices other than Class I require a conformity assessment agreement with an EU-established Notified Body, together with financial coverage under Article 10(16).